What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Immune system
His primary areas of study are Immunology, Antigen, Immune system, Melanoma and Immunotherapy.
The Immunology study combines topics in areas such as Cytotoxic T cell, Peripheral blood mononuclear cell and Cancer.
His Antigen research includes elements of Antibody and Virology.
His Immune system research incorporates elements of Vaccination and Effector.
His biological study spans a wide range of topics, including Oncology, Peptide vaccine, Internal medicine, Lymphocyte and In vivo.
His studies in Immunotherapy integrate themes in fields like Malignant transformation, Cancer research, CCL5 and Adoptive cell transfer.
His most cited work include:
- Molecular classification of cutaneous malignant melanoma by gene expression profiling (1861 citations)
- Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma (1702 citations)
- A human memory T cell subset with stem cell-like properties (1070 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Immunology, Immune system, Immunotherapy, Cancer and Melanoma.
Immunology is frequently linked to Cytotoxic T cell in his study.
His work deals with themes such as Molecular biology and CD8, which intersect with Cytotoxic T cell.
His Immune system research is multidisciplinary, incorporating perspectives in Cancer cell, Peripheral blood mononuclear cell and Cytokine.
His Immunotherapy research includes themes of Immunization, Oncology and Bioinformatics.
Francesco M. Marincola interconnects Tumor-infiltrating lymphocytes and Pathology in the investigation of issues within Melanoma.
He most often published in these fields:
- Immunology (50.10%)
- Immune system (32.60%)
- Immunotherapy (30.42%)
What were the highlights of his more recent work (between 2012-2021)?
- Immune system (32.60%)
- Immunotherapy (30.42%)
- Cancer (23.46%)
In recent papers he was focusing on the following fields of study:
Francesco M. Marincola mainly focuses on Immune system, Immunotherapy, Cancer, Immunology and Internal medicine.
His Immune system research integrates issues from Cancer cell, Cancer research and Gene.
His Immunotherapy study combines topics in areas such as Cancer therapy, Melanoma, Cell therapy and Bioinformatics.
Francesco M. Marincola works mostly in the field of Cancer, limiting it down to concerns involving Neuroscience and, occasionally, Immune checkpoint inhibitors.
Many of his studies on Immunology apply to Cytotoxic T cell as well.
In his research on the topic of Internal medicine, Clinical trial, Breast cancer, Colorectal cancer and Interleukin 6 is strongly related with Oncology.
Between 2012 and 2021, his most popular works were:
- Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. (794 citations)
- Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. (223 citations)
- Memory T cell–driven differentiation of naive cells impairs adoptive immunotherapy (132 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Immune system
His main research concerns Immunology, Immunotherapy, Immune system, Cancer and Cancer research.
His studies deal with areas such as Cytotoxic T cell and Peripheral blood mononuclear cell as well as Immunology.
His work carried out in the field of Immunotherapy brings together such families of science as Hypoxia, Melanoma, Oncology and Antigen.
His work on T cell as part of general Immune system research is frequently linked to Working group and Milestone, thereby connecting diverse disciplines of science.
In general Cancer, his work in Cancer immunotherapy is often linked to Rules of engagement linking many areas of study.
His research in Cancer research intersects with topics in Cell, PI3K/AKT/mTOR pathway and FOXP3.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
